Lung Cancer: Still the Top Cancer Killer
Recent news of the full results of the National Lung Screening Trial (NLST) published in the New England Journal of Medicine underscores the heavy toll… Read More »Lung Cancer: Still the Top Cancer Killer
Recent news of the full results of the National Lung Screening Trial (NLST) published in the New England Journal of Medicine underscores the heavy toll… Read More »Lung Cancer: Still the Top Cancer Killer
Three stories top the list of major developments in cancer research during the past month. Listen to these topics discussed in the most recent Cancer News Review podcast.
First, to treat or not to treat is the question for low-risk prostate cancer. Whether to give aggressive treatments for low-risk cancer contained within the prostate is a controversy that many experts in the field still debate. Prostate cancer expert and Kimmel Cancer Center director William Nelson reviews a study analyzing how treatment decisions for these cancers are made and how quality of life expectations are communicated. He says the current problem is that screening, which has helped decrease mortality from prostate cancer, has identified some men who could live their entire lives with prostate cancer but die of other causes. He believes there are certain groups of men who should consider active surveillance programs to carefully monitor low-risk, organ-confined prostate cancer.
Starting in 2002, more than 50,000 current and former smokers aged 55 to 74 signed up for the National Lung Screening Trial (NLST) at Johns Hopkins and more than 30 other sites across the nation. The trial was to last 10 years, but eight years into the study, leaders of the trial found their results thus far were significant enough to stop the trial and announce their findings.